181 related articles for article (PubMed ID: 28526299)
1. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
Georgantas RW; Streicher K; Luo X; Greenlees L; Zhu W; Liu Z; Brohawn P; Morehouse C; Higgs BW; Richman L; Jallal B; Yao Y; Ranade K
Pigment Cell Melanoma Res; 2014 Mar; 27(2):275-86. PubMed ID: 24289491
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma.
Chen X; Wang J; Shen H; Lu J; Li C; Hu DN; Dong XD; Yan D; Tu L
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1193-9. PubMed ID: 21051724
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-29c induces G1 arrest of melanoma by targeting CDK6.
Yang H; Shen C
J BUON; 2019; 24(2):819-825. PubMed ID: 31128041
[TBL] [Abstract][Full Text] [Related]
5. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
6. A Temperature Sensitive Variant of p53 Drives p53-Dependent MicroRNA Expression without Evidence of Widespread Post-Transcriptional Gene Silencing.
Cabrita MA; Vanzyl EJ; Hamill JD; Pan E; Marcellus KA; Tolls VJ; Alonzi RC; Pastic A; Rambo TM; Sayed H; McKay BC
PLoS One; 2016; 11(2):e0148529. PubMed ID: 26840126
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma.
Chen X; He D; Dong XD; Dong F; Wang J; Wang L; Tang J; Hu DN; Yan D; Tu L
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2248-56. PubMed ID: 23404119
[TBL] [Abstract][Full Text] [Related]
8. miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression.
Li S; Wang C; Yu X; Wu H; Hu J; Wang S; Ye Z
Oncol Rep; 2017 Jan; 37(1):241-248. PubMed ID: 27878260
[TBL] [Abstract][Full Text] [Related]
9. MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer.
Zhang Q; Feng Y; Liu P; Yang J
Tumour Biol; 2017 Jul; 39(7):1010428317711312. PubMed ID: 28718369
[TBL] [Abstract][Full Text] [Related]
10. Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4.
Qin Y; Zhou X; Huang C; Li L; Liu H; Liang N; Chen Y; Ma D; Han Z; Xu X; He J; Li S
Gene; 2018 Oct; 675():278-284. PubMed ID: 29935356
[TBL] [Abstract][Full Text] [Related]
11. Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
[TBL] [Abstract][Full Text] [Related]
12. Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.
van Kempen LC; van den Hurk K; Lazar V; Michiels S; Winnepenninckx V; Stas M; Spatz A; van den Oord JJ
Virchows Arch; 2012 Oct; 461(4):441-8. PubMed ID: 22956368
[TBL] [Abstract][Full Text] [Related]
13. miR-6883 Family miRNAs Target CDK4/6 to Induce G
Lulla AR; Slifker MJ; Zhou Y; Lev A; Einarson MB; Dicker DT; El-Deiry WS
Cancer Res; 2017 Dec; 77(24):6902-6913. PubMed ID: 29061672
[TBL] [Abstract][Full Text] [Related]
14. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma.
Bhattacharya A; Schmitz U; Wolkenhauer O; Schönherr M; Raatz Y; Kunz M
Oncogene; 2013 Jun; 32(26):3175-83. PubMed ID: 22847610
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 Cascade.
Rambow F; Bechadergue A; Luciani F; Gros G; Domingues M; Bonaventure J; Meurice G; Marine JC; Larue L
J Invest Dermatol; 2016 Jun; 136(6):1229-1237. PubMed ID: 26968260
[TBL] [Abstract][Full Text] [Related]
17. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
Yang C; Li Z; Bhatt T; Dickler M; Giri D; Scaltriti M; Baselga J; Rosen N; Chandarlapaty S
Oncogene; 2017 Apr; 36(16):2255-2264. PubMed ID: 27748766
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma.
Li R; Zhang L; Jia L; Duan Y; Li Y; Wang J; Bao L; Sha N
PLoS One; 2014; 9(4):e94855. PubMed ID: 24722758
[TBL] [Abstract][Full Text] [Related]
19. A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence.
Acevedo M; Vernier M; Mignacca L; Lessard F; Huot G; Moiseeva O; Bourdeau V; Ferbeyre G
Cancer Res; 2016 Jun; 76(11):3252-64. PubMed ID: 27206849
[TBL] [Abstract][Full Text] [Related]
20. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
